Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis. Issue 16 (23rd April 2021)

• Record Type: Journal Article
• Authors: Son, James J.; Ishimori, Mariko; Mirocha, James; Weisman, Michael H.; Forbess, Lindsy J.
• Other Names: Jaiswal. Hemant section editor.
• Is Part Of: Medicine. Volume 100:Issue 16(2021)
• Publication Date: 2021-04-23
• Subjects: ACPA -- anticyclic citrullinated peptide antibodies -- CCP -- CCP3.1 -- citrullinated cyclic peptide -- diagnostic performance -- rheumatoid arthritis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000025558
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Our aim was to investigate the newest generation anti-cyclic citrullinated peptide (CCP) antibody 3.1 assay in diagnosing rheumatoid arthritis (RA) compared with other autoimmune and non-autoimmune diseases. We performed a retrospective observational chart review of patients with a positive CCP level over a one-year period at a single academic institution and assessed the associated diagnoses after at least six-months of follow-up. Of the 281 CCP positive patients during that period, 48% had a diagnosis of RA. The positive predictive value of RA in patients with a high CCP 3.1 assay was 0.619 compared to 0.248 with a low positive CCP 3.1 assay ( P < .0001). Overall, there was a lower than expected positive predictive value of CCP 3.1 level with an RA diagnosis, though the likelihood of having an RA diagnosis was higher with a higher CCP level. Abstract : Supplemental Digital Content is available in the text